Herantis Pharma Oyj Sustainability Reports
Herantis Pharma Oyj is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease. Its leading product candidate is HER-096, a small peptidomimetic engineered to penetrate the blood-brain barrier and stop or reverse neurodegeneration.
Sector: Manufacturing
Country: Finland
Exchange: Nasdaq Helsinki
LEI: 743700W4CQVYAT3WKK38
FIGI: BBG006GWBH71
8 reports from 2016 to 2025
